New Digital Cancer Diagnostics Partnership Announced Between LUMEA, Inc., and Southern Utah University

Share Article

Accelerating the development of new digital cancer diagnostics in the field of pathology is the aim of a new partnership between diagnostics pioneer LUMEA, Inc. and Southern Utah University (SUU).

Accelerating the development of new digital cancer diagnostics in the field of pathology is the aim of a new partnership between diagnostics pioneer LUMEA, Inc. and Southern Utah University (SUU).

LUMEA is sponsoring the Digital Diagnostic Medical Research Initiative (DDx-MRI) at SUU to bring internationally recognized medical experts to the campus for research sabbaticals.

Dr. Matthew O. Leavitt, founder and chief medical officer of LUMEA, said the collaboration “will open up research opportunities to expand LUMEA’s ability to advance the way all cancer biopsies are processed, handled and evaluated.”

The first scholar-in-residence for DDx-MRI is Dr. Sorin Musat, Ph.D/MD, an anatomical pathologist from Romania and founder of a biotech firm in Canada. He holds a number of patents in pathology and introduced the first tissue microarray in routine clinical diagnostics. Musat is a graduate of Carol Davila University in Bucharest.

“SUU is an ideal environment for multi-partner research collaboration,” said Robert Eves, dean of the Walter Maxwell Gibson College of Science and Engineering at SUU. “The university is interested in providing quality experiences for faculty and students and welcomes research collaboration.”

Through the initiative, SUU students can apply for scholarships or college credit as they engage with the scholars-in-residence. The Initiative will provide research opportunities for students interested in histology, engineering or medical research.

Housing and travel expenses for scholars-in-residence are made possible through donations from the Dixie and Anne Leavitt Family Foundation SUU is providing research space and a venue for visiting faculty summer seminars. Research funding for DDx-MRI projects will be provided by LUMEA.

LUMEA, Inc.
LUMEA’s mission is to standardize and improve cancer diagnostics. It developed the first integrated biopsy-to-digital diagnostic platform that improves tissue handling, modernizes the pathology process, and enables the commercialization of diagnostic artificial intelligence (AI). LUMEA was founded by Dr. Matthew O. Leavitt, a Stanford-trained pathologist, who has dedicated his career to changing and improving cancer diagnostics. The Orem, Utah- based company was founded in 2014 and has 27 employees all working together to save lives by revolutionizing diagnostic medicine.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Abigail Wyatt
LUMEA
+1 4355921866
Email >
@LUMEA_DDx
since: 01/2018
Follow >
Visit website